Effect of the clopidogrel - Proton Pump Inhibitor drug interaction on adverse cardiovascular events in patients with Acute Coronary Syndrome

Pharmacotherapy

Volumn 32, Issue 9, 2012, Pages 809-818

  Bhurke, Sharvari M ^a   Martin, Bradley C ^b   Li, Chenghui ^b   Franks, Amy M ^c   Bursac, Zoran ^c   Said, Qayyim ^b  

^a Analytica International   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acute; Adverse; Cardiovascular; Clopidogrel; Coronary; Events; Inhibitors; Interaction; Outcomes; Proton; Pump; Syndrome

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; INTERMEDIATE CORONARY SYNDROME; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TICLOPIDINE; TIME FACTORS;

EID: 84867585759     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01112.x     Document Type: Article

References (36)

1. Cardiovascular Disease Statistics. Available from: http://circ. ahajournals.org/content/121/7/e46.full.pdf. Accessed 27th January 2012.
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007;50 (7):e1-e157. No abstract available. Erratum in: J Am Coll Cardiol. 2008 Mar 4;51(9):974.
3. Mehta SR, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21(24):2033-2041.
4. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ, CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention; insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Hear J 2009;157:369-374.
5. Medline Plus: Clopidogrel. Available from: http://www.nlm. nih.gov/medlineplus/druginfo/meds/a601040.html#skip Accessed 22nd November 2009.
6. The US Food and Drug Administration. Information on Clopidogrel Bisulfate (marketed as Plavix). Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm. Accessed 30th November 2010.
7. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374(9694):989-997. Epub 2009 Aug 31. Review.
8. The US Food and Drug Administration. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm 079520.htm. Accessed 7th June 2010.
9. The US Food and Drug Administration. FDA Announces New Warning on Plavix: Avoid Use with Prilosec/Prilosec OTC. Available from: http://www.fda.gov/ newsEvents/Newsroom/PressAnnouncements/ucm191169.htm. Accessed 7th June 2010
10. The US Food and Drug Administration. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm. Accessed 22nd November 2009.
11. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301(9):937-944.
12. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180(7):713-718. Epub 2009 Jan 28.
13. Stockl KM, Le L, Zakharyan A, et al. Risk of Rehospitalization for patients using clopidogrel with proton pump inhibitors. Arch Intern Med 2010;170(8):704-710.
14. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52(12):1038-1039. author reply 1039.
15. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010;55(7):1964-1968.
16. Huang CC, Chen YC, Leu HB, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010;105(12):1705-1709. Epub 2010 Apr 27.
17. Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010;30(8):787-796.
18. Schmidt M, Johansen MB, Robertson DJ, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 2012;35(1):165-174. doi: 10.1111/j.1365-2036.2011.04890.x. Epub 2011 Nov 4.
19. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009;120(23):2322-2329. Epub 2009 Nov 23.
20. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152(6):337-345.
21. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153(6):378-386.
22. Erratum in: Ann Intern Med. 2011 Jan 4;154(1):76.
23. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011;20(10):1043-1049. doi: 10.1002/pds.2202. Epub 2011 Aug 8.
24. Sarafoff N, Sibbing D, Sonntag U, et al. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost 2010;104(3):626-632. Epub 2010 Jul 20.
25. Stricker BH, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population- based cohort studies. Eur J Epidemiol 2010;25(4):245-251. Epub 2010 Apr 1.
26. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol 2006;163(12):1149-1156. Epub 2006 Apr 19.
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-763. Review.
28. Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54(13):1149-1153.
29. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51(3):256-260.
30. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101(4):714-719.
31. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48(4):475-484. Epub 2008 Feb 26.
32. Van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105(11):2430-2436; quiz 2437. Epub 2010 Aug 24. Erratum in: Am J Gastroenterol. 2010 Nov;105(11):2516.
33. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. COGENT Investigators. N Engl J Med. 2010;363(20):1909-1917. Epub 2010 Oct 6.
34. Blackburn DF, Lamb DA, Mcleod MM, Eurich DT. Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies. Pharmacotherapy 2010;30(10):985-993.
35. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 2009;29(6):661-677. Epub 2009 Aug 14.
36. Zarowitz BJ. Clopidogrel: with or without a proton pump inhibitor? Geriatr Nurs 2009;30:188-192.